Skip to main content
OpenTrials

Clinical trial condition

Prostatic Neoplasms, Castration-Resistant

Explore clinical trials studying Prostatic Neoplasms, Castration-Resistant. Study availability and eligibility vary by location and protocol.

57 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Prostatic Neoplasms, Castration-Resistant trial results

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Arizona Clinical Trials Chandler, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • MemorialCare Orange Coast Medical Center Fountain Valley, California, United States
  • University Of California San Diego La Jolla, California, United States
View all 150 locations
View Trial Details
Recruiting

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07719361

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +15 more
Locations
  • START Los Angeles Los Angeles, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • START Midwest Grand Rapids, Michigan, United States
  • START New Jersey East Brunswick, New Jersey, United States
View Trial Details
Recruiting

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

NCT07717268

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Hospital Universitario Miguel Servet Zaragoza, Aragon, Spain
  • Hospital Clinic de Barcelona Barcelona, Spain
  • Instituto Catalán de Oncología Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Universitario Basurto Bilbao, Basque Country, Spain
View all 15 locations
View Trial Details
Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272

Conditions
Castration-Resistant Prostatic Cancer, Genital Diseases, Genital Diseases, Male, +14 more
Locations
  • UCLA Hematology & Oncology ( Site 0003) Los Angeles, California, United States
  • University of California-Irvine Medical Center ( Site 0016) Orange, California, United States
  • UCSF Medical Center at Mission Bay ( Site 0034) San Francisco, California, United States
  • MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026) Washington D.C., District of Columbia, United States
View all 82 locations
View Trial Details
Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Investigational Site Number: 403 Palo Alto, California, United States
  • Investigational Site Number: 401 Houston, Texas, United States
  • Investigational Site number: 404 Fairfax, Virginia, United States
  • Investigational Site Number: 400 Seattle, Washington, United States
View Trial Details
Recruiting

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

NCT07258407

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Yale University, Yale Cancer Center New Haven, Connecticut, United States
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
  • Institut Bergonié Bordeaux, France
View Trial Details
Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • UCSD Moores Cancer Center ( Site 0039) La Jolla, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0044) Los Angeles, California, United States
  • University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 0051) Miami, Florida, United States
  • University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0049) Baltimore, Maryland, United States
View all 77 locations
View Trial Details
Recruiting

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Stanford Cancer Institute Stanford, California, United States
  • East Jefferson General Hospital River Ridge, Louisiana, United States
  • BAMF Health Grand Rapids, Michigan, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details

Related conditions